NASDAQ:AKCAAkcea Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akcea Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.90 -0.20 (-1.32 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$14.45Now: $14.90▼$15.1450-Day Range$14.15MA: $15.90▼$18.0052-Week Range$8.00Now: $14.90▼$25.66Volume310,655 shsAverage Volume199,118 shsMarket Capitalization$1.51 billionP/E RatioN/ADividend YieldN/ABeta1.33 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAkcea Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.67, Akcea Therapeutics has a potential upside of 132.7% from its current price of $14.90.Amount of Analyst CoverageAkcea Therapeutics has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesAkcea Therapeutics has received 334 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAkcea Therapeutics has received 348 “underperform” votes. (Add your “underperform” vote.)Community SentimentAkcea Therapeutics has received 51.03% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote “Outperform” if you believe AKCA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAkcea Therapeutics does not currently pay a dividend.Dividend GrowthAkcea Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akcea Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $123,743.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Akcea Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 20.15% of the stock of Akcea Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Akcea Therapeutics are expected to decrease in the coming year, from ($1.37) to ($1.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akcea Therapeutics is -49.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akcea Therapeutics is -49.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkcea Therapeutics has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.16 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKCA Previous Symbol CUSIPN/A CIK1662524 Webwww.akceatx.com Phone617-207-0202Debt Debt-to-Equity Ratio0.03 Current Ratio12.63 Quick Ratio12.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$488.54 million Price / Sales3.08 Cash Flow$0.51 per share Price / Cash Flow29.19 Book Value$5.04 per share Price / Book2.96Profitability EPS (Most Recent Fiscal Year)$0.48 Net Income$40.77 million Net Margins-8.59% Return on Equity-6.70% Return on Assets-5.92%Miscellaneous Employees248 Outstanding Shares101,070,000Market Cap$1.51 billion Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:AKCA Rates by TradingView Receive AKCA News and Ratings via Email Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter. Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions How has Akcea Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Akcea Therapeutics' stock was trading at $13.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AKCA stock has increased by 10.9% and is now trading at $14.90. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Akcea Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akcea Therapeutics. When is Akcea Therapeutics' next earnings date? Akcea Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Akcea Therapeutics. How were Akcea Therapeutics' earnings last quarter? Akcea Therapeutics Inc (NASDAQ:AKCA) posted its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.03. The firm had revenue of $16.07 million for the quarter, compared to analyst estimates of $34.85 million. Akcea Therapeutics had a negative return on equity of 6.70% and a negative net margin of 8.59%. Akcea Therapeutics's revenue for the quarter was down 90.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.15 EPS. View Akcea Therapeutics' earnings history. What price target have analysts set for AKCA? 4 equities research analysts have issued 12-month price objectives for Akcea Therapeutics' stock. Their forecasts range from $24.00 to $41.00. On average, they expect Akcea Therapeutics' stock price to reach $34.67 in the next twelve months. This suggests a possible upside of 132.7% from the stock's current price. View analysts' price targets for Akcea Therapeutics. Has Akcea Therapeutics been receiving favorable news coverage? News articles about AKCA stock have been trending very negative on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akcea Therapeutics earned a news sentiment score of -3.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutAkcea Therapeutics. Who are some of Akcea Therapeutics' key competitors? Some companies that are related to Akcea Therapeutics include United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), PPD (SDGR), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Nektar Therapeutics (NKTR), ChemoCentryx (CCXI), GW Pharmaceuticals PLC- (GWPH) and Biohaven Pharmaceutical (BHVN). View all competitors. What other stocks do shareholders of Akcea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Apollo Global Management (APO), Associated British Foods (ABF) and Chaarat Gold (CGH). Who are Akcea Therapeutics' key executives? Akcea Therapeutics' management team includes the following people: Ms. Paula Soteropoulos, CEO & Director (Age 51)Mr. Michael F. MacLean, Chief Financial Officer (Age 53)Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)Ms. Sarah Boyce, Pres & Director (Age 47)Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46) When did Akcea Therapeutics IPO? (AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager. What is Akcea Therapeutics' stock symbol? Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA." Who are Akcea Therapeutics' major shareholders? Akcea Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.79%), State Street Corp (0.67%), Geode Capital Management LLC (0.27%), Alps Advisors Inc. (0.17%), Nuveen Asset Management LLC (0.08%) and Russell Investments Group Ltd. (0.07%). Company insiders that own Akcea Therapeutics stock include Damien Mcdevitt, Jeff Marc Goldberg, Joshua F Patterson, Kyle Jenne, Paula Soteropoulos and Sarah Boyce. View institutional ownership trends for Akcea Therapeutics. Which major investors are selling Akcea Therapeutics stock? AKCA stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, BlackRock Inc., Russell Investments Group Ltd., Alps Advisors Inc., Tudor Investment Corp Et Al, Morgan Stanley, Wells Fargo & Company MN, and Deutsche Bank AG. Company insiders that have sold Akcea Therapeutics company stock in the last year include Damien Mcdevitt, Joshua F Patterson, Kyle Jenne, and Sarah Boyce. View insider buying and selling activity for Akcea Therapeutics. Which major investors are buying Akcea Therapeutics stock? AKCA stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Geode Capital Management LLC, Dynamic Technology Lab Private Ltd, Nuveen Asset Management LLC, Aigen Investment Management LP, State Street Corp, Mackenzie Financial Corp, and SG Americas Securities LLC. View insider buying and selling activity for Akcea Therapeutics. How do I buy shares of Akcea Therapeutics? Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Akcea Therapeutics' stock price today? One share of AKCA stock can currently be purchased for approximately $14.90. How big of a company is Akcea Therapeutics? Akcea Therapeutics has a market capitalization of $1.51 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe. What is Akcea Therapeutics' official website? The official website for Akcea Therapeutics is www.akceatx.com. How can I contact Akcea Therapeutics? Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected] This page was last updated on 5/31/2020 by MarketBeat.com Staff
